文献速递肿瘤 PET/CT核素与放射性配体治疗

治疗前68Ga-PSMA-617 PET可提示177Lu-PSMA-617与177Lu-EB-PSMA-617的剂量学

Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions.
PubMed 文献 · Clin Nucl Med · 2019-01-01

该研究纳入9例转移性去势抵抗性前列腺癌患者,治疗前行68Ga-PSMA-617 PET/CT,其中5例接受177Lu-PSMA-617、4例接受177Lu-EB-PSMA-617并系列显像计算剂量。结果显示治疗前SUV与主要器官有效剂量及肿瘤吸收剂量相关,提示可用于筛选肽受体放射性核素治疗候选者,仍需更大样本验证。

要点

  • 治疗前68Ga-PSMA-617 PET的SUV与主要器官有效剂量呈中度相关。
  • 肿瘤病灶SUV与177Lu-PSMA-617相关性高,与177Lu-EB-PSMA-617呈中度相关。
  • 该关系可能有助于筛选肽受体放射性核素治疗的合适候选者。

核心结论

  • 治疗前68Ga-PSMA-617 PET可能提示177Lu-PSMA-617和177Lu-EB-PSMA-617的剂量学。
  • 主要器官有效剂量和肿瘤病灶吸收剂量均与68Ga-PSMA-617 PET的SUV相关。

研究设计与样本

  • 单中心研究,经机构审查委员会批准并获知情同意后招募9例mCRPC患者。
  • 9例均行68Ga-PSMA-617 PET/CT扫描。
  • 5例接受177Lu-PSMA-617(1.30-1.42 GBq,35-38.4 mCi),于0.5、2、24、48、72小时行全身平面显像及胸腹部SPECT/CT。
  • 4例接受177Lu-EB-PSMA-617(0.80-1.1 GBq,21.5-30 mCi),于2、24、72、120、168小时行相同显像。
  • 计算主要器官有效剂量与肿瘤病灶吸收剂量并分析其与治疗前SUV的相关性。

主要发现

  • 治疗前SUV与主要器官有效剂量呈中度相关:177Lu-PSMA-617 r=0.610,177Lu-EB-PSMA-617 r=0.743,均P<0.001。
  • 肿瘤病灶治疗前SUV与177Lu-PSMA-617相关性强:r=0.915,P<0.001。
  • 肿瘤病灶治疗前SUV与177Lu-EB-PSMA-617呈中度相关:r=0.611,P=0.002。

临床怎么用

  • 可考虑以治疗前68Ga-PSMA-617 PET的SUV辅助预判主要器官有效剂量与肿瘤吸收剂量。
  • 该关系可能帮助筛选适合肽受体放射性核素治疗的患者。

局限性

  • 样本量小(共9例),需更大队列研究确认初步发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Combined Ga-PSMA-617 PET imaging and Lu-PSMA-617 therapy is a precise targeted theranostic approach for patients with metastatic castration-resistant prostate cancer (mCRPC). The purpose of this study was to determine whether pretherapeutic standard uptake value (SUV) in Ga-PSMA-617 PET could indicate the effective dose in the main organs and absorbed dose in tumor lesions. METHODS: After institutional review board approval and informed consent, 9 patients with mCRPC were recruited and underwent Ga-PSMA-617 PET/CT scans. Five patients received Lu-PSMA-617 (1.30-1.42 GBq, 35-38.4 mCi) and then underwent serial whole-body planar imaging and SPECT/CT imaging of both thoracic and abdominal regions at 0.5-, 2-, 24-, 48-, and 72-hour time points. The other 4 patients received Lu-EB-PSMA-617 (0.80-1.1 GBq, 21.5-30 mCi) and then underwent the same imaging procedures at 2-, 24-, 72-, 120-, and 168-hour time points. The effective dose in the main organs and the absorbed dose in tumor lesions were calculated. Detailed correlations between the pretherapeutic SUV in Ga-PSMA-617 PET and effective dose in the main organs as well as absorbed dose in the tumor lesions were analyzed. RESULTS: SUV of Ga-PSMA-617 PET was moderately correlated with effective dose in main organs (r = 0.610 for Lu-PSMA-617, r = 0.743 for Lu-EB-PSMA-617, both P < 0.001). SUV of tumor lesions in Ga-PSMA-617 PET had high correlation with those in Lu-PSMA-617 (r = 0.915, P < 0.001) and moderate correlation with those in Lu-EB-PSMA-617 (r = 0.611, P = 0.002). CONCLUSIONS: Pretherapeutic Ga-PSMA-617 PET may indicate the dosimetry of Lu-PSMA-617 and Lu-EB-PSMA-617. Both the effective dose in main organs and absorbed dose in tumor lesions correlate with SUV of Ga-PSMA-617 PET. This relationship may help select appropriate candidates for peptide receptor radionuclide therapy. Further investigations of larger cohorts are needed to confirm these initial findings.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wang J, Zang J, Wang H, et al. Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions. Clin Nucl Med. 2019. PMID: 30985422. doi:10.1097/RLU.0000000000002575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。